Open Access

Prognostic factors for overall survival and safety of trans-arterial chemoembolization (TACE) with irinotecan-loaded drug-eluting beads (DEBIRI) in patients with colorectal liver metastases

Maja Sljivic

Maja Sljivic

  • Faculty of Medicine LjubljanaLjubljana, Slovenia
  • Clinical Institute of Radiology, University Medical Centre LjubljanaLjubljana, Slovenia
Search for this author on
Sciendo|Google Scholar
Sljivic, Maja
, 
Masa Sever

Masa Sever

Faculty of Medicine BelgradeSerbia
Search for this author on
Sciendo|Google Scholar
Sever, Masa
, 
Janja Ocvirk

Janja Ocvirk

  • Faculty of Medicine LjubljanaLjubljana, Slovenia
  • Institute of OncologyLjubljana, Slovenia
  • University of Primorska, Faculty of Health SciencesIsola, Slovenia
Search for this author on
Sciendo|Google Scholar
Ocvirk, Janja
, 
Tanja Mesti

Tanja Mesti

  • Faculty of Medicine LjubljanaLjubljana, Slovenia
  • Institute of OncologyLjubljana, Slovenia
Search for this author on
Sciendo|Google Scholar
Mesti, Tanja
, 
Erik Brecelj

Erik Brecelj

  • Faculty of Medicine LjubljanaLjubljana, Slovenia
  • Institute of OncologyLjubljana, Slovenia
Search for this author on
Sciendo|Google Scholar
Brecelj, Erik
 and 
Peter Popovic

Peter Popovic

  • Faculty of Medicine LjubljanaLjubljana, Slovenia
  • Clinical Institute of Radiology, University Medical Centre LjubljanaLjubljana, Slovenia
Search for this author on
Sciendo|Google Scholar
Popovic, Peter
  
Mar 30, 2024
Prognostic factors for overall survival and safety of trans-arterial chemoembolization (TACE) with irinotecan-loaded drug-eluting beads (DEBIRI) in patients with colorectal liver metastases's Cover Image
About this article
Previous Article
Next Article
Cite
Download Cover
Article Category: Research Article
Published Online: Mar 30, 2024
Page range: 214 - 220
Received: Dec 13, 2023
Accepted: Mar 06, 2024
DOI: https://doi.org/10.2478/raon-2024-0023
Keywords
© 2024 Maja Sljivic et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.

FIGURE 1.

Overall survival (OS) from the beginning of irinotecan-loaded drug-eluting beads (DEBIRI) treatment.
Overall survival (OS) from the beginning of irinotecan-loaded drug-eluting beads (DEBIRI) treatment.

FIGURE 2.

Progression-free survival (PFS) from the beginning of irinotecan-loaded drug-eluting beads (DEBIRI) treatment.
Progression-free survival (PFS) from the beginning of irinotecan-loaded drug-eluting beads (DEBIRI) treatment.

FIGURE 3.

Overall survival (OS) of patients with prior systemic chemotherapy from the beginning of systemic treatment.
Overall survival (OS) of patients with prior systemic chemotherapy from the beginning of systemic treatment.

FIGURE 4.

Progression-free survival (PFS) of patients with prior systemic chemotherapy from the beginning of systemic treatment.
Progression-free survival (PFS) of patients with prior systemic chemotherapy from the beginning of systemic treatment.

Patient demographics and clinicopathological features

Age in years
  Median (range) 68 (34–85)
Sex n (%)
  Male 22 (73)
  Female 8 (27)
Primary tumour
  Colon 16 (53)
  Rectum 14 (47)
ECOG performance status
  0 18 (60)
  1 9 (30)
  2 3 (10)
Liver metastases
  Unilobar 17 (57)
  Bilobar 13 (43)
  ≤ 4 lesions 19 (63)
  > 4 lesions 11 (37)
Previous chemotherapy
  Yes 17 (57)
  No 13 (43)

Univariate analysis – influence of probable prognostic factors on overall survival

Characteristics n (%) OS 95 % CI p-value
Age ≤ 65 years 11 (37) 15.2 8.5–21.8 0.284
Age > 65 years 19 (63) 21.6 4.7–38.4.
Colon 16 (53) 23.7 16.8–30.5 0.145
Rectum 14 (47) 14.1 6.8–21.4
ECOG 0 18 (60) 19.8 11.3–28.4 0.805
ECOG 1 or 2 12 (40) 17.4 10.0–29.7
Previous chemotherapy 17 (57) 17.4 11.0–23.7 0.472
No previous chemotherapy 13 (43) 21.6 3.8–39.4
Unilobar disease 17 (57) 23.5 7.4–39.6 0.106
Bilobar disease 13 (43) 15.2 1.9–28.4
≤ 4 liver lesions 19 (63) 23.5 15.5–31.5 0.002
> 4 liver lesions 11 (37) 10.8 0.3–21.3
CEA ≤ 5 µg/L before the first DEBIRI TACE 5 (27) 17.4 5.9–28.9 0.591
CEA > 5 µg/L before the first DEBIRI TACE 22 (73) 15.2 9.2–21.1
Increase of serum CEA after first DEBIRI TACE 10 (33) 14.1 7.3–20.9 0.037
Decrease of serum CEA after first DEBIRI TACE 12 (40) 24.7 7.0–42.4
CEA stayed the same 1 (3) 25.5
CA 19-9 ≤ 37 kU/L before first DEBIRI TACE 16 (53) 15.2 10.1–20.2 0.393
CA 19-9 > 37 kU/L before first DEBIRI TACE 11 (47) 17.4 0.5–34.2
Increase of serum CA 19-9 after first DEBIRI TACE 11 (48) 15.2 11.7–18.7 0.583
Decrease of serum CA 19-9 after first DEBIRI TACE 10 (43) 19.8 0.0–44.9
CA 19-9 stayed the same 2 (9) 7.4
Language:
English
Publication timeframe:
4 times per year
Journal Subjects:
Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology, Radiology
Journal RSS Feed